

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657

Vimta 

Driven by Quality. Inspired by Science.

VLL\SE\061\2022-23

Date: 27.01.2023

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001
Scrip Code No.524394

Asst Vice President
National Stock Exchange of India
Limited
“Exchange Plaza”, Bandra
Kurla Complex, Bandra (E)
Mumbai – 400051
Trading Symbol: VIMTALABS

Dear Sirs,

Sub - Outcome of the Board Meeting.

Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, please find enclosed herewith Standalone and Consolidated Unaudited Financial Results for the third quarter ended 31st December 2022, along with Limited Review Report. Copy of the Unaudited Financial results are also posted on the company’s website i.e., <https://vimta.com/investors/financial-statements/>. Abridged financials are being published in the newspapers (copy enclosed).

The meeting commenced at 11:30 AM and ended at 03:00 PM


This is for your information and records.

Thanking you,

Yours faithfully,
for VIMTA LABS LIMITED



Sujani Vasireddi
Company Secretary



Encl: as above.

Independent Auditor's Review Report on Standalone Unaudited Quarterly and year to date Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of VIMTA LABS LIMITED

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Company'), for the quarter ended 31 December 2022 and the year to date results for the period 01 April 2022 to 31 December 2022, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 27-01-2023



for GATTAMANENI & CO.
Chartered Accountants
(Firm Regn.No.009303S)

G. SRINIVASARAO
Partner
ICAI Ms. No.210535
UDIN: 23210535BGXUSG6958

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2022
(Amount in INR millions, except Earnings Per Share)

| S. No. | Particulars | Quarter Ended | | | Nine Months ended | | Year Ended |
|-----------|--|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------|
| | | 31 Dec 22 (Unaudited) | 30 Sep 22 (Unaudited) | 31 Dec 21 (Unaudited) | 31 Dec 22 (Unaudited) | 31 Dec 21 (Unaudited) | 31 Mar 22 (Audited) |
| 1 | Income from operations | | | | | | |
| | (a) Revenue from operations (Refer note no. 5) | 764.97 | 791.32 | 666.80 | 2,343.13 | 2,023.81 | 2,759.80 |
| | (b) Other income | 11.32 | 7.71 | 7.24 | 28.03 | 10.35 | 14.54 |
| | Total Income | 776.29 | 799.03 | 674.04 | 2,371.16 | 2,034.16 | 2,774.34 |
| 2 | Expenses | | | | | | |
| | (a) Cost of materials consumed and testing expenditure | 172.03 | 165.37 | 166.04 | 526.66 | 494.49 | 646.13 |
| | (b) Cost of lab setup (Refer note no. 5) | 14.92 | 0.97 | 14.37 | 19.20 | 118.42 | 138.43 |
| | (c) Purchase of stock-in-trade | - | - | - | - | - | - |
| | (d) Changes in inventories of work-in-progress | 0.10 | 0.16 | 0.17 | 0.41 | 2.45 | 2.66 |
| | (e) Employee benefits expense (Refer note no. 6) | 228.76 | 231.09 | 191.23 | 685.32 | 545.17 | 754.13 |
| | (f) Finance costs | 6.53 | 7.99 | 2.48 | 23.96 | 9.22 | 14.96 |
| | (g) Depreciation expense | 78.03 | 75.32 | 55.41 | 225.42 | 165.14 | 231.58 |
| | (h) Other expenses | 138.96 | 142.51 | 91.14 | 411.66 | 296.28 | 420.73 |
| | Total Expenses | 639.33 | 623.41 | 520.84 | 1,892.63 | 1,631.17 | 2,208.62 |
| 3 | Profit/(Loss) before exceptional items and tax [1-2] | 136.96 | 175.62 | 153.20 | 478.53 | 402.99 | 565.72 |
| 4 | Exceptional items | - | - | - | - | 12.24 | 12.24 |
| 5 | Profit/(Loss) before tax [3-4] | 136.96 | 175.62 | 153.20 | 478.53 | 390.75 | 553.48 |
| 6 | Tax expense | | | | | | |
| | (a) Current tax | 41.99 | 54.13 | 40.89 | 143.31 | 114.66 | 148.75 |
| | (b) Taxes of earlier periods | 2.80 | - | - | 6.92 | - | 4.48 |
| | (c) Deferred tax (benefit)/expense | (7.39) | (9.14) | (3.34) | (22.19) | (15.73) | (10.33) |
| | Total Tax Expense | 37.40 | 44.99 | 37.55 | 128.04 | 98.93 | 142.90 |
| 7 | Profit/(Loss) for the period (5-6) | 99.56 | 130.63 | 115.65 | 350.49 | 291.82 | 410.58 |
| 8 | Other Comprehensive Income/(expense), net of tax expenses | | | | | | |
| | <i>Items that will not be reclassified subsequently to profit or loss :</i> | | | | | | |
| | (a) Re-measurements of net defined benefit liability | (0.84) | (0.84) | 0.59 | (2.52) | 1.68 | (2.71) |
| | (b) Income tax relating to the items | 0.21 | 0.21 | (0.15) | 0.63 | (0.42) | 0.68 |
| | Total other comprehensive income/(loss), net of tax | (0.63) | (0.63) | 0.44 | (1.89) | 1.26 | (2.03) |
| 9 | Total Comprehensive Income for the period (comprising Profit/(Loss) and other Comprehensive income for the period [7+8]) | 98.93 | 130.00 | 116.09 | 348.60 | 293.08 | 408.55 |
| 10 | Paid-up Equity Share Capital (Face value of Rs.2/- per equity share) | 44.25 | 44.22 | 44.22 | 44.25 | 44.22 | 44.22 |
| 11 | Other Equity | | | | | | 2,292.27 |
| 12 | Earnings per equity share (EPS) (Face value of Rs.2 per share) | | | | | | |
| | (a) Basic (INR) | 4.50 | 5.91 | 5.23 | 15.84 | 13.20 | 18.57 |
| | (b) Diluted (INR) | 4.39 | 5.80 | 5.11 | 15.51 | 12.91 | 18.20 |
| | (EPS for the quarter ended are not annualised) | | | | | | |



Notes to the results :

- 1 The above unaudited standalone financial results for the quarter and nine months ended December 31, 2022 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 27, 2023.
- 2 The results for the quarter and nine months ended December 31, 2022 were subjected to 'Review' by the statutory auditors of the company. An unmodified report was issued by them thereon.
- 3 These unaudited standalone financials results of the Company are prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India ("SEBI") in this regard.
- 4 The management has identified the reportable segments in accordance with the requirements of Ind AS-108 'Operating Segments', and decided that the Company has only one reportable segment, viz. 'Contract Research and Testing Services'.
- 5 During the quarter ended June 30, 2021, the company has entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT, Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a "Service Concessionaire Arrangement" (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset. Consequently, the amount of revenues from operations and lab setup expenses includes ₹ 14.92 million for the quarter ended December 31, 2022, ₹ 19.20 million for nine months ended December 31, 2022 and ₹ 138.43 million for the year ended March 31, 2022, respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively.
- 6 Pursuant to ' Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)', during the quarter ended December 31, 2022, the company has allotted 15,019 Equity shares of ₹ 2 each upon exercise of Employee stock options by the eligible employees. Accordingly, the paid up share capital of the company stands increased from ₹44.22 million to ₹44.25 million.

Further, the committee granted 53,663 options to the eligible employees during the period ended December 31, 2022. In respect of stock options granted pursuant to the Company's stock options plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense includes ₹9.37 million for the quarter ended December 31, 2022, ₹35.39 million for nine months ended December 31, 2022 and ₹28.97 million for the year ended March 31, 2022.
- 7 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment received Presidential assent in September 2020 and its effective date is yet to be notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period when the Code becomes effective.
- 8 The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.

For and on behalf of the Board of Directors of
Vimta Labs Limited

CIN: L24110TG1990PLC011977



Harita Vasireddi
Managing Director

Place : Hyderabad, INDIA
Date : January 27, 2023



Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2022
(Amount in INR millions, except Earnings Per Share)

| S. No. | Particulars | Quarter Ended | | | Nine Months ended | | Year ended |
|--------|--|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------|
| | | 31 Dec 22 (Unaudited) | 30 Sep 22 (Unaudited) | 31 Dec 21 (Unaudited) | 31 Dec 22 (Unaudited) | 31 Dec 21 (Unaudited) | 31 Mar 22 (Audited) |
| 1 | Total Income from Operations | 764.97 | 791.32 | 666.80 | 2,343.13 | 2,023.81 | 2,759.80 |
| 2 | Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items) | 136.96 | 175.62 | 153.20 | 478.53 | 402.99 | 565.72 |
| 3 | Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items) | 136.96 | 175.62 | 153.20 | 478.53 | 390.75 | 553.48 |
| 4 | Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items) | 99.56 | 130.63 | 115.65 | 350.49 | 291.82 | 410.58 |
| 5 | Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] | 98.93 | 130.00 | 116.09 | 348.60 | 293.08 | 408.55 |
| 6 | Equity Share Capital | 44.25 | 44.22 | 44.22 | 44.25 | 44.22 | 44.22 |
| 7 | Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year | | | | | | 2,292.27 |
| 8 | Earnings Per Share (of Rs.2/- each) (for continuing and discontinued Operations) | | | | | | |
| | 1. Basic (INR) | 4.50 | 5.91 | 5.23 | 15.84 | 13.20 | 18.57 |
| | 2. Diluted (INR) | 4.39 | 5.80 | 5.11 | 15.51 | 12.91 | 18.20 |

Notes :

- The above is an extract of the detailed format of Quarterly and Nine months ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Company's Website (www.vimta.com) and on the websites of BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).
- The above unaudited standalone financial results for the quarter and nine months ended December 31, 2022 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 27, 2023.
- Figures of the previous periods have been regrouped/recast/reclassified wherever considered necessary.

For and on behalf of the Board of Directors of
Vimta Labs Limited
CIN: L24110TG1990PLC011977



Harita Vasireddi
Managing Director

Place : Hyderabad, INDIA
Date : January 27, 2023



Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of VIMTA LABS LIMITED

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Holding Company') and M/s.EMTAC Laboratories Private Limited, wholly owned subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), for the quarter ended 31 December 2022 and the year to date results for the period 01 April 2022 to 31 December 2022, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.



We also performed procedures in accordance with Circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 27-01-2023

for GATTAMANENI & CO.
Chartered Accountants
(Firm Regn.No.009303S)



A handwritten signature in blue ink, appearing to read "G. Srinivasarao".

G. SRINIVASARAO
Partner
ICAI Ms. No.210535
UDIN: 23210535BGXUSH7259

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months Ended December 31, 2022
(Amount in INR millions, except Earnings Per Share)

| S. No. | Particulars | Quarter Ended | | | Nine Months Ended | | Year ended |
|--------|--|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------|
| | | 31 Dec 22 (Unaudited) | 30 Sep 22 (Unaudited) | 31 Dec 21 (Unaudited) | 31 Dec 22 (Unaudited) | 31 Dec 21 (Unaudited) | 31 Mar 22 (Audited) |
| 1 | Income from operations | | | | | | |
| | (a) Revenue from operations (Refer note no. 5) | 773.84 | 798.54 | 673.40 | 2,363.70 | 2,041.91 | 2,782.79 |
| | (b) Other income | 11.24 | 7.62 | 7.14 | 27.77 | 10.10 | 14.49 |
| | Total Income | 785.08 | 806.16 | 680.54 | 2,391.47 | 2,052.01 | 2,797.28 |
| 2 | Expenses | | | | | | |
| | (a) Cost of materials consumed and testing expenditure | 173.03 | 166.26 | 167.43 | 529.22 | 497.97 | 650.87 |
| | (b) Cost of lab setup (Refer note no. 5) | 14.92 | 0.97 | 14.37 | 19.20 | 118.42 | 138.43 |
| | (c) Purchase of stock-in-trade | - | - | - | - | - | - |
| | (d) Changes in inventories of work-in-progress | 0.10 | 0.16 | 0.17 | 0.41 | 2.45 | 2.66 |
| | (e) Employee benefits expense (Refer note no. 6) | 230.64 | 233.03 | 192.62 | 690.80 | 549.15 | 759.81 |
| | (f) Finance costs | 6.53 | 8.00 | 2.48 | 23.97 | 9.23 | 14.98 |
| | (g) Depreciation expense | 78.47 | 75.75 | 55.84 | 226.72 | 166.44 | 233.29 |
| | (h) Other expenses | 140.60 | 144.39 | 92.86 | 416.72 | 301.52 | 428.15 |
| | Total Expenses | 644.29 | 628.56 | 525.77 | 1,907.04 | 1,645.18 | 2,228.19 |
| 3 | Profit/(Loss) before exceptional items and tax [1-2] | 140.79 | 177.60 | 154.77 | 484.43 | 406.83 | 569.09 |
| 4 | Exceptional items | - | - | - | - | 12.24 | 12.24 |
| 5 | Profit/(Loss) before tax [3-4] | 140.79 | 177.60 | 154.77 | 484.43 | 394.59 | 556.85 |
| 6 | Tax expense | | | | | | |
| | (a) Current tax | 43.10 | 54.66 | 41.35 | 145.00 | 115.53 | 149.37 |
| | (b) Taxes of earlier periods | 2.80 | - | - | 6.92 | - | 4.48 |
| | (c) Deferred tax (benefit)/expense | (7.52) | (9.17) | (3.40) | (22.38) | (15.90) | (10.30) |
| | Total Tax Expense | 38.38 | 45.49 | 37.95 | 129.54 | 99.63 | 143.55 |
| 7 | Profit/(Loss) for the period (5-6) | 102.41 | 132.11 | 116.82 | 354.89 | 294.96 | 413.30 |
| 8 | Other Comprehensive Income/(expense), net of tax expenses | | | | | | |
| | <i>Items that will not be reclassified subsequently to profit or loss :</i> | | | | | | |
| | (a) Re-measurements of net defined benefit liability | (0.84) | (0.84) | 0.59 | (2.52) | 1.68 | (2.71) |
| | (b) Income tax relating to the items | 0.21 | 0.21 | (0.15) | 0.63 | (0.42) | 0.68 |
| | Total other comprehensive income/(loss), net of tax | (0.63) | (0.63) | 0.44 | (1.89) | 1.26 | (2.03) |
| 9 | Total Comprehensive Income for the period (comprising Profit/(Loss) and other Comprehensive income for the period [7+8]) | 101.78 | 131.48 | 117.26 | 353.00 | 296.22 | 411.27 |
| 10 | Paid-up Equity Share Capital (Face value of Rs.2/- per equity share) | 44.25 | 44.22 | 44.22 | 44.25 | 44.22 | 44.22 |
| 11 | Other Equity | | | | | | 2,295.62 |
| 12 | Earnings per equity share (EPS) (Face value of Rs.2 per share) | | | | | | |
| | (a) Basic (INR) | 4.62 | 5.97 | 5.28 | 16.04 | 13.34 | 18.70 |
| | (b) Diluted (INR) | 4.51 | 5.85 | 5.17 | 15.71 | 13.04 | 18.32 |
| | (EPS for the quarter ended are not annualised) | | | | | | |



Handwritten signatures of the management.




Notes to the results :

- 1 The above unaudited consolidated financial results for the quarter and nine months ended December 31, 2022 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 27, 2023.
- 2 The results for the quarter and nine months ended December 31, 2022 were subjected to 'Review' by the statutory auditors of the company. An unmodified report was issued by them thereon.
- 3 These unaudited consolidated financials results of the Company are prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India ("SEBI") in this regard.
- 4 The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating Segment' and states that the Group has only one reportable segment namely 'Contract Research and Testing Services'.
- 5 During the quarter ended June 30, 2021, the company has entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT, Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a "Service Concessionaire Arrangement" (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset. Consequently, the amount of revenues from operations and lab setup expenses includes ₹ 14.92 million for the quarter ended December 31, 2022, ₹ 19.20 million for nine months ended December 31, 2022 and ₹ 138.43 million for the year ended March 31, 2022, respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively.
- 6 Pursuant to ' Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)', during the quarter ended December 31, 2022, the company has allotted 15,019 Equity shares of ₹ 2 each upon exercise of Employee stock options by the eligible employees. Accordingly, the paid up share capital of the company stands increased from ₹44.22 million to ₹44.25 million.

Further, the committee granted 53,663 options to the eligible employees during the period ended December 31, 2022. In respect of stock options granted pursuant to the Company's stock options plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense includes ₹9.37 million for the quarter ended December 31, 2022, ₹35.39 million for nine months ended December 31, 2022 and ₹28.97 million for the year ended March 31, 2022.
- 7 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment received Presidential assent in September 2020 and its effective date is yet to be notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period when the Code becomes effective.
- 8 The previous periods figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.

For and on behalf of the Board of Directors of
Vimta Labs Limited
CIN: L24110TG1990PLC011977



Harita Vasireddi
Managing Director

Place : Hyderabad, INDIA
Date : January 27, 2023



Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months Ended December 31, 2022
(Amount in INR millions, except Earnings Per Share)

| S. No. | Particulars | Quarter Ended | | | Nine Months Ended | | Year ended |
|--------|--|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------|
| | | 31 Dec 22 (Unaudited) | 30 Sep 22 (Unaudited) | 31 Dec 21 (Unaudited) | 31 Dec 22 (Unaudited) | 31 Dec 21 (Unaudited) | 31 Mar 22 (Audited) |
| 1 | Total Income from Operations | 773.84 | 798.54 | 673.40 | 2,363.70 | 2,041.91 | 2,782.79 |
| 2 | Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items) | 140.79 | 177.60 | 154.77 | 484.43 | 406.83 | 569.09 |
| 3 | Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items) | 140.79 | 177.60 | 154.77 | 484.43 | 394.59 | 556.85 |
| 4 | Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items) | 102.41 | 132.11 | 116.82 | 354.89 | 294.96 | 413.30 |
| 5 | Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] | 101.78 | 131.48 | 117.26 | 353.00 | 296.22 | 411.27 |
| 6 | Equity Share Capital | 44.25 | 44.22 | 44.22 | 44.25 | 44.22 | 44.22 |
| 7 | Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year | | | | | | 2,295.62 |
| 8 | Earnings Per Share (of Rs.2/- each) (for continuing and discontinued Operations) | | | | | | |
| | 1. Basic (INR) | 4.62 | 5.97 | 5.28 | 16.04 | 13.34 | 18.70 |
| | 2. Diluted (INR) | 4.51 | 5.85 | 5.17 | 15.71 | 13.04 | 18.32 |

Notes :

- The above is an extract of the detailed format of Quarterly and Nine months ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Company's Website (www.vimta.com) and on the websites of BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).
- The above unaudited consolidated financial results for the quarter and nine months ended December 31, 2022 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 27, 2023.
- Figures of the previous periods have been regrouped/recast/reclassified wherever considered necessary.

For and on behalf of the Board of Directors of
Vimta Labs Limited
CIN: L24110TG1990PLC011977



Harita Vasireddi
Managing Director

Place : Hyderabad, INDIA
Date : January 27, 2023

